Medytox candidates bolster Allergan's neurotoxin pipeline
This article was originally published in Scrip
Executive Summary
In an apparent move to build on its large and growing Botox franchise, Allergan has paid $65m up front to acquire worldwide rights outside South Korea to selected neurotoxin product candidates being developed by the small South Korean firm Medytox.